Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 4/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6530375 | 0.90 | ACP1 (0.49) | ACP1ABCG2ADORA2ACYP19A1LMNA | |
| SCHEMBL6001448 | 0.86 | ACP1 (0.68) | ACP1ADORA2ALMNAHPGDSMN1; SMN2 | |
| SCHEMBL4031738 | 0.84 | DHODH (0.45) | ACP1ABCG2ADORA2A | |
| SCHEMBL4823424 | 0.84 | MAP4K4 (0.43) | ACP1ABCG2ADORA2ALMNAHPGD | |
| SCHEMBL4025078 | 0.84 | RXFP1 (0.42) | ACP1ABCG2ADORA2AHPGD | |
| SCHEMBL4026356 | 0.82 | NT5E (0.43) | ACP1ABCG2ADORA2AHPGDSMN1; SMN2 | |
| SCHEMBL4032316 | 0.81 | CYP1A2 (0.46) | ACP1ABCG2ADORA2ALMNAHPGD | |
| SCHEMBL4025761 | 0.80 | NT5E (0.44) | ACP1ABCG2ADORA2AHPGD | |
| SCHEMBL4022559 | 0.79 | NT5E (0.49) | ACP1ABCG2ACHETDP1 | |
| SCHEMBL4820926 | 0.79 | ABCG2 (0.51) | ABCG2SMN1; SMN2ALDH1A1MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348340-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2008-03-25 | — | — | US | disclosed |
| US-20070129363-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
| US-20040053964-A1 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
| EP-1339706-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002036586-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053964-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1E, CACNA1B, CACNA1A | ACP1 2483/4885ABCG2 1532/4885ADORA2A 317/4885 |
| US-20070129363-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | CACNA1B, CACNA1E, CACNA1G | ACP1 2923/4885ABCG2 1064/4885ADORA2A 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.